KOSDAQElectronic Components498150

MBD

Offer price ₩7,000 · Listing date 2026-11-24
Market Cap
—
Turnover
—
Volume
—
Shares out.
14.3M
PER
—
PBR
—
EPS
—
Dividend Yield
—

Prices and metrics are added after the listing-day close

01

Report overview

Recapitalized, but operating losses persist

MBD's equity turned positive by end-June 2026, but operating losses continue, so whether its operating results turn around after listing is the key variable.

  1. 1

    The demand forecast drew 187.10 to 1 from 925 institutions, while the final offering price of KRW 7,000 came in 27.1% below the low end of the indicative range.

  2. 2

    The offering size shrank from an expected KRW 19.2 billion to KRW 23.4 billion to KRW 14 billion, and the expected post-listing market capitalization is KRW 100.4 billion.

  3. 3

    Total equity moved from KRW -39.2 billion at end-2025 to KRW 12.8 billion at end-June 2026, ending the capital impairment.

  4. 4

    Operating losses were recorded in each year from 2023 to 2025 and continued in the first half of 2026 at KRW 4.16 billion.

  5. 5

    Net proceeds of KRW 13.7 billion are planned for facilities, operating funds, and the acquisition of equity in other companies.

02

Business structure

MBD, founded in 2015, is a 3D cell culture automation company that applies process control technology developed in precision manufacturing to biological experiments.

Its core product is the ASFA platform, which automates pretreatment, micro-dispensing, culture, and image analysis in one workflow, with the ASFA Spotter dispensing unit and the ASFA Scanner analysis unit as its main instruments.

The equipment business is supplemented by in-house dedicated plates (Cellvitro), culture reagents, and the PhenoSW analysis software, so the company supplies instruments together with consumables and software.

The precision medicine segment is OncoSensi, an anticancer drug sensitivity test that grows patient-derived cancer cells in 3D to compare drug responses, and the company says it has secured 45 cooperating hospitals in Korea.

The drug development CRO segment uses the same platform to treat patient-derived 3D cell models with candidate compounds and evaluate efficacy and responsiveness.

The company frames equipment, precision medicine, and CRO as three pillars and says data from patient-derived cells and drug responses accumulated across them are shared.

It argues that 2D culture cannot reproduce the three-dimensional structure of human tissue and that animal models differ biologically from humans, so demand for 3D culture and the automated equipment that runs it is growing.

On competition, MBD points to automation that reduces variability from manual culture work and an integrated model covering in-house consumables and analysis software.

Overseas, it plans to expand supply through partnerships with global equipment companies that already have sales networks, reducing the burden of building its own sales organization.

03

Recent trends

According to the financial summary in the securities registration statement (K-IFRS, unqualified audit opinions), revenue was KRW 872 million in 2023, KRW 242 million in 2024 (down 72.3% year on year), and KRW 1.52 billion in 2025 (up 530.6% year on year), making 2025 the largest year of the three.

Operating losses were KRW 5.27 billion in 2023, KRW 6.2 billion in 2024, and KRW 5.63 billion in 2025, a third consecutive year of losses, with the 2025 loss narrower than in 2024. Net losses were KRW 7.49 billion in 2023, KRW 11 billion in 2024, and KRW 2.13 billion in 2025, also three consecutive years of losses.

At end-December 2025, total assets were KRW 17.5 billion, total liabilities were KRW 56.7 billion, and total equity was KRW -39.2 billion, meaning the company was in a state of capital impairment.

For the first half of 2026 (January to June, cumulative), revenue was KRW 890 million, operating loss was KRW 4.16 billion, and net income was KRW 11.2 billion. These first-half figures follow K-IFRS and were reviewed, not audited, by Samjong Accounting Corporation.

At end-June 2026, total assets were KRW 17.9 billion, total liabilities were KRW 5.05 billion, and total equity was KRW 12.8 billion, ending the capital impairment. First-half revenue of KRW 890 million exceeds half of full-year 2025 revenue of KRW 1.52 billion.

Net income turned positive while operating losses continued, which suggests non-operating items had a large effect, although the composition is not shown in the summary. The large shifts in equity and liabilities within six months are not explained by the summary alone.

04

Outlook

The direction of future results depends on whether MBD can narrow operating losses enough to reach profitability and whether the improvement in capital structure carries through to operations.

Whether the operating loss of KRW 4.16 billion recorded in the first half of 2026 continues in the second half is the first point to watch.

In equipment, expansion of ASFA overseas supply is the key variable, and because consumables and software sales tend to follow instrument placements, whether the recurring revenue share actually rises is the central test.

In precision medicine, the company plans to widen the cancer types and referring hospitals for OncoSensi and to accumulate clinical evidence.

Of the KRW 13.7 billion in net proceeds, KRW 3.23 billion is allocated to facilities, KRW 4.5 billion to operating funds, and KRW 6 billion to the acquisition of equity in other companies, and the company says the facilities funds will expand production capacity for ASFA instruments and dedicated consumables.

Whether that capacity translates into higher sales is the next point to verify. The target and effects of the equity acquisition will become clear through later disclosures.

The CRO business grows with pharmaceutical demand for candidate compound evaluation, and the company is pursuing overseas customers through global partners.

05

Bull factors

Broad institutional demand

The institutional demand forecast drew 187.10 to 1 from 925 institutions. Demand remained broad even though the final price was set below the low end of the indicative range, which shows that institutions paid attention to the business despite the reduced offering size and valuation.

Capital impairment resolved

Total equity moved from KRW -39.2 billion at end-2025 to KRW 12.8 billion at end-June 2026, and total liabilities fell from KRW 56.7 billion to KRW 5.05 billion over the same period.

The end of capital impairment improves the balance sheet compared with the prior year-end, although the drivers of the change are not shown in the summary.

Technology and clinical data base

MBD received A and BBB grades in a technology evaluation in October 2025. The company says it holds 13,000 clinical samples and cooperation with 45 hospitals.

If demand for 3D culture equipment continues to grow as the company describes, its combination of automated instruments and clinical data could benefit from that demand.

06

Bear factors

Three years of operating losses on small revenue

MBD recorded operating losses in each year from 2023 to 2025, and 2025 revenue was only KRW 1.52 billion. The operating loss continued at KRW 4.16 billion in the first half of 2026. The size of operating losses relative to revenue leaves the path to breakeven long, which is the main bearish point.

Downward revision of offering terms

The final price of KRW 7,000 was 27.1% below the low end and 40.2% below the high end of the indicative range.

The offering size fell from an expected KRW 19.2 billion to KRW 23.4 billion to KRW 14 billion, and the expected post-listing market capitalization fell from about KRW 167.8 billion at the top of the range to KRW 100.4 billion.

Limited quantitative proof of recurring and overseas revenue

The company highlights recurring revenue from consumables and software after instrument sales. However, the summary financial information does not show the share of consumables and software in total revenue or the share of overseas sales.

The first-half 2026 net income turning positive may reflect non-operating items, so the evidence for operating improvement is limited.

07

Risk factors

Macro

Recent reports indicate that several companies withdrew listings during a period of cooling institutional demand, while MBD chose to list at a lower offering price. If capital flows and new-listing demand weaken across the market, trading conditions after listing could also change. Interest rates and sentiment in the IPO market are the main drivers.

Business and clinical

For OncoSensi results to be used in actual treatment, clinical evidence must accumulate and adoption in medical settings must expand. The company itself identifies expanding cancer types, referring institutions, and clinical evidence as priorities. A slower build-up of clinical evidence could constrain growth in the precision medicine segment.

Overseas partnership

Overseas supply relies on the sales networks of global equipment companies, so results may depend on partner relationships and contract terms. The strategy reduces the company's own sales burden, but changes in partner strategy would affect overseas revenue plans.

The target of the KRW 6 billion equity acquisition is not yet disclosed in detail, which adds uncertainty about business focus.

08

Overall view

MBD operates 3D cell culture automation equipment, precision medicine, and drug development CRO services and is newly listing on KOSDAQ, with its listing date set for November 24, 2026. The 187.10 to 1 demand forecast competition rate and the end of capital impairment by end-June 2026 are confirmed positive factors.

On the other side, operating losses continued for three consecutive years from 2023 to 2025 and reached KRW 4.16 billion in the first half of 2026. The final offering price was set 27.1% below the low end of the indicative range, and the offering size was reduced.

After listing, the central test is whether operating losses narrow, whether overseas ASFA supply and consumables sales grow, and whether OncoSensi adoption widens in measurable terms.

The execution of the KRW 13.7 billion in net proceeds and the effect of the equity acquisition will become clear through later disclosures. This verdict is a qualitative summary based on disclosures and reporting.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. fetv.co.kr
  2. m.news.nate.com
  3. newspost.kr
  4. thebionews.net
  5. thebionews.net
  6. pinpointnews.co.kr
  7. news1.kr
  8. newstopkorea.com
  9. thebionews.net
  10. news.bizwatch.co.kr
  11. edaily.co.kr

Report written 2026-11-21 · Data as of 2026-11-20

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.